Barchart.com
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
0.5767 +0.0101 (+1.78%) 13:23 ET [NASDAQ]
0.5713 x 1 0.5779 x 5
Realtime by (Cboe BZX)
0.5713 x 1 0.5779 x 5
Realtime 0.5700 +0.0034 (-) 09:30 ET
News & Headlines for Thu, Apr 24th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action Newswire.ca - Thu Apr 24, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz Newswire.ca - Mon Apr 14, 9:10AM CDT

/CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...

ONCY : 0.5767 (+1.78%)
ONC : 255.17 (+2.42%)
CVM : 0.2918 (+1.60%)
ONC.TO : 0.79 (unch)
ATNM : 1.3300 (+2.31%)
OSTX : 1.5800 (+1.94%)
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments BayStreet.ca - Mon Apr 14, 8:24AM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Routine medical appointments or cancer screening rates—an important aspect in increasing survival...

ONCY : 0.5767 (+1.78%)
URGN : 10.02 (-1.76%)
NVS : 110.97 (+0.76%)
PHIO : 2.18 (+6.86%)
ONC.TO : 0.79 (unch)
HURA : 4.14 (-1.43%)
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital Newswire.ca - Thu Apr 10, 5:09PM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
Private Sector Steps Up in Cancer Research as Federal Support Wavers BayStreet.ca - Thu Apr 10, 9:08AM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH), questions...

ONCY : 0.5767 (+1.78%)
SMMT : 34.04 (+2.44%)
CADL : 4.99 (+4.83%)
IMTX : 4.61 (+2.22%)
EXEL : 37.26 (+1.31%)
ONC.TO : 0.79 (unch)
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers Newswire.ca - Thu Apr 10, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge Newswire.ca - Sat Mar 8, 6:33AM CST

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.5767 (+1.78%)
EXEL : 37.26 (+1.31%)
ONC.TO : 0.79 (unch)
ALXO : 0.6105 (+5.26%)
CRDF : 2.85 (-3.06%)
VSTM : 7.30 (+2.53%)
Stocks in play: Oncolytics Biotech Inc Baystreet - Fri Mar 7, 8:40AM CST

Announces reporting on highlights and financial results for Q4 and year-end 2024. With its lead candidate, ...

ONCY : 0.5767 (+1.78%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 BayStreet.ca - Fri Mar 7, 8:20AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.5500 (-3.73%)
ONCY : 0.5767 (+1.78%)
TARA : 4.20 (+0.95%)
YMAB : 4.07 (-1.33%)
FATE : 1.3400 (+0.75%)
ONC.TO : 0.79 (unch)
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 Newswire.ca - Fri Mar 7, 6:00AM CST

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 Newswire.ca - Thu Feb 27, 9:04AM CST

/CNW/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being...

ONCY : 0.5767 (+1.78%)
GNTA : 4.05 (+5.74%)
CELC : 10.99 (-0.72%)
NYT : 50.41 (-0.06%)
SLS : 1.3400 (+2.29%)
ONC.TO : 0.79 (unch)
AMGN : 279.26 (+0.49%)
World Cancer Day Sparks Big Questions About Pollution, Genetics, and Innovation BayStreet.ca - Thu Feb 27, 8:58AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As World Cancer Day (Feb. 4) fades into the rearview, attention is shifting to the latest discussions...

ONCY : 0.5767 (+1.78%)
ZNTL : 1.4750 (-1.67%)
NYT : 50.41 (-0.06%)
ABSI : 3.19 (+0.32%)
GOVX : 0.9688 (+14.25%)
ONC.TO : 0.79 (unch)
GSK : 37.35 (+0.86%)
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Newswire.ca - Tue Feb 25, 6:00AM CST

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
Investors Eye Biotech Sector as Cancer Therapy Market Surges Newswire.ca - Wed Feb 19, 9:06AM CST

/CNW/ -- USA News Group News Commentary – Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven data...

ONCY : 0.5767 (+1.78%)
RENB : 0.3796 (+1.06%)
POAI : 1.0500 (+9.68%)
DGX : 175.58 (+1.16%)
GRAL : 35.93 (+6.43%)
ONC.TO : 0.79 (unch)
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 Newswire.ca - Wed Feb 19, 6:00AM CST

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer FinancialNewsMedia - Tue Feb 18, 10:25AM CST

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins FinancialNewsMedia - Tue Feb 18, 10:24AM CST

Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause...

ONCY : 0.5767 (+1.78%)
ALLO : 1.5500 (-3.73%)
VRCA : 0.4552 (-0.76%)
ONC.TO : 0.79 (unch)
OSTX : 1.5800 (+1.94%)
IBRX : 2.65 (-1.49%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins BayStreet.ca - Tue Feb 18, 8:05AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers),...

ALLO : 1.5500 (-3.73%)
ONCY : 0.5767 (+1.78%)
VRCA : 0.4552 (-0.76%)
ONC.TO : 0.79 (unch)
IBRX : 2.65 (-1.49%)
OSTX : 1.5800 (+1.94%)
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer Newswire.ca - Tue Feb 18, 6:00AM CST

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency Newswire.ca - Fri Feb 14, 4:15PM CST

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.5767 (+1.78%)
ONC.TO : 0.79 (unch)

Barchart Exclusives

Unusual Options Activity: Toast Makes a Tasty LEAP for Conservative Investors Barchart - 9 minutes ago
Toast had one unusually active option on Wednesday among the 1,053 puts and calls, but it’s all the conservative investor needs to make a bet on the fast-growing restaurant software business. Here’s why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective
Wed, Apr 30, 2025 5:00 PM UTC
Reserve Your Spot